Physician Wealth Advisors Inc. Purchases Shares of 598 Zoetis Inc. (NYSE:ZTS)

Physician Wealth Advisors Inc. acquired a new position in Zoetis Inc. (NYSE:ZTS) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 598 shares of the company’s stock, valued at approximately $97,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Callahan Advisors LLC raised its position in Zoetis by 90.4% during the 4th quarter. Callahan Advisors LLC now owns 13,105 shares of the company’s stock worth $2,135,000 after buying an additional 6,221 shares during the last quarter. CIBC Asset Management Inc raised its holdings in shares of Zoetis by 24.1% during the fourth quarter. CIBC Asset Management Inc now owns 237,369 shares of the company’s stock worth $38,617,000 after purchasing an additional 46,050 shares during the last quarter. Pensionfund Sabic lifted its position in Zoetis by 55.6% during the fourth quarter. Pensionfund Sabic now owns 11,200 shares of the company’s stock valued at $1,825,000 after purchasing an additional 4,000 shares during the period. PFW Advisors LLC purchased a new stake in Zoetis in the fourth quarter valued at $1,764,000. Finally, Alberta Investment Management Corp grew its position in Zoetis by 2,050.0% during the 4th quarter. Alberta Investment Management Corp now owns 30,100 shares of the company’s stock worth $4,904,000 after purchasing an additional 28,700 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total value of $55,804.68. Following the transaction, the executive vice president now directly owns 16,107 shares of the company’s stock, valued at approximately $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Willie M. Reed sold 1,210 shares of the company’s stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the sale, the director now directly owns 11,245 shares of the company’s stock, valued at approximately $1,868,244.30. This represents a 9.71 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,862 shares of company stock valued at $312,254 in the last 90 days. 0.16% of the stock is owned by insiders.

Analyst Ratings Changes

Several equities analysts have recently issued reports on ZTS shares. UBS Group assumed coverage on Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective for the company. Piper Sandler boosted their price target on Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a report on Thursday, February 27th. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. StockNews.com upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. Finally, Leerink Partners started coverage on shares of Zoetis in a research report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target on the stock. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $215.90.

Zoetis Stock Down 1.2 %

ZTS opened at $163.03 on Monday. The company has a market cap of $73.00 billion, a PE ratio of 29.80, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.33. The company has a 50-day moving average price of $166.40 and a 200 day moving average price of $174.44. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping the consensus estimate of $1.37 by $0.03. The company had revenue of $2.32 billion during the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. Sell-side analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be issued a $0.50 dividend. The ex-dividend date is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a yield of 1.23%. Zoetis’s payout ratio is currently 36.56%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.